Parkin-mediated protection of dopaminergic neurons in a chronic MPTP-minipump mouse model of parkinson disease

Journal of Neuropathology and Experimental Neurology

Volumn 70, Issue 8, 2011, Pages 686-697

  Yasuda, Toru ^a,b   Hayakawa, Hideki ^a,b   Nihira, Tomoko ^a,b   Ren, Yong Ri ^a,b   Nakata, Yasuto ^a   Nagai, Makiko ^a   Hattori, Nobutaka ^b   Miyake, Koichi ^c   Takada, Masahiko ^d   Shimada, Takashi ^c   Mizuno, Yoshikuni ^a,b   Mochizuki, Hideki ^a,b  

^a KITASATO UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

^c NIPPON MEDICAL SCHOOL   (Japan)

^d KYOTO UNIVERSITY   (Japan)

Author keywords

Synuclein; Adeno associated virus; MPTP; Neuroprotection; Osmotic minipump; Parkin; Parkinson disease

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOVIRUS VECTOR; ALPHA SYNUCLEIN; PARKIN; PROTEIN KINASE B; PROTEIN P53; SERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL LOSS; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; DRUG MEGADOSE; IMMUNOCOMPETENT CELL; IMMUNOREACTIVITY; MALE; MITOCHONDRION; MOUSE; NEUROPROTECTION; NONHUMAN; OSMOTIC MINIPUMP; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; UPREGULATION;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ALPHA-SYNUCLEIN; ANALYSIS OF VARIANCE; ANIMALS; BCL-2-ASSOCIATED X PROTEIN; CELL COUNT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; GENE EXPRESSION REGULATION; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; HUMANS; MALE; MESENCEPHALON; MICE; MICE, INBRED C57BL; MICROINJECTIONS; MOTOR ACTIVITY; MPTP POISONING; NERVE DEGENERATION; NEURONS; NEUROTOXINS; ONCOGENE PROTEIN V-AKT; ROTAROD PERFORMANCE TEST; SIGNAL TRANSDUCTION; STATISTICS AS TOPIC; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN-PROTEIN LIGASES;

EID: 79961029955     PISSN: 00223069     EISSN: 15546578     Source Type: Journal    
DOI: 10.1097/NEN.0b013e3182269ecd     Document Type: Article

References (57)

1. Farrer MJ. Genetics of Parkinson disease: Paradigm shifts and future prospects. Nat Rev Genet 2006;7:306-18
2. Shults CW. Lewy bodies. Proc Natl Acad Sci U S A 2006;103:1661-68 (Pubitemid 43228751)
3. Dauer W, Przedborski S. Parkinson's disease: Mechanisms and models. Neuron 2003;39:889-909 (Pubitemid 37130207)
4. Kitada T, Asakawa S, Hattori N, et al. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature 1998;392:605-8 (Pubitemid 28207717)
5. Shimura H, Hattori N, Kubo S, et al. Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase. Nat Genet 2000;25:302-5 (Pubitemid 30437317)
6. Takahashi H, Ohama E, Suzuki S, et al. Familial juvenile parkinsonism: Clinical and pathologic study in a family. Neurology 1994;44:437-41 (Pubitemid 24098141)
7. Mori H, Kondo T, Yokochi M. Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q. Neurology 1998;51:890-92 (Pubitemid 28449284)
8. Hayashi S, Wakabayashi K, Ishikawa A, et al. An autopsy case of autosomal-recessive juvenile parkinsonism with a homozygous exon 4 deletion in the parkin gene. Mov Disord 2000;15:884-88
9. van de Warrenburg BP, Lammens M, Lucking CB, et al. Clinical and pathologic abnormalities in a family with parkinsonism and parkin gene mutations. Neurology 2001;56:555-57 (Pubitemid 32172889)
10. Savitt JM, Dawson VL, Dawson TM. Diagnosis and treatment of Parkinson disease: Molecules to medicine. J Clin Invest 2006;116:1744-54 (Pubitemid 44033293)
11. Moore DJ. Parkin: A multifaceted ubiquitin ligase. Biochem Soc Trans 2006;34:749-53 (Pubitemid 44796412)
12. Lim KL, Chew KC, Tan JM, et al. Parkin mediates nonclassical, proteasomal-independent ubiquitination of synphilin-1: Implications for Lewy body formation. J Neurosci 2005;25:2002-9 (Pubitemid 40289405)
13. Lim KL, Dawson VL, Dawson TM. Parkin-mediated lysine 63-linked polyubiquitination: A link to protein inclusions formation in Parkinson's and other conformational diseases? Neurobiol Aging 2006;27:524-29 (Pubitemid 43290521)
14. Doss-Pepe EW, Chen L, Madura K. alpha-Synuclein and parkin contribute to the assembly of ubiquitin lysine 63-linked multiubiquitin chains. J Biol Chem 2005;280:16619-24 (Pubitemid 41389118)
15. Mukhopadhyay D, Riezman H. Proteasome-independent functions of ubiquitin in endocytosis and signaling. Science 2007;315:201-5 (Pubitemid 46166358)
16. Yasuda T, Mochizuki H. The regulatory role of alpha-synuclein and parkin in neuronal cell apoptosis: Possible implications for the pathogenesis of Parkinson's disease. Apoptosis 2010;15:1312-21
17. Palacino JJ, Sagi D, Goldberg MS, et al. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004;279:18614-22 (Pubitemid 38623283)
18. Kitada T, Pisani A, Karouani M, et al. Impaired dopamine release and synaptic plasticity in the striatum of parkin-/-mice. J Neurochem 2009;110:613-21
19. Frank-Cannon TC, Tran T, Ruhn KA, et al. Parkin deficiency increases vulnerability to inflammation-related nigral degeneration. J Neurosci 2008;28:10825-34
20. Chung KK, Thomas B, Li X, et al. S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function. Science 2004;304:1328-31 (Pubitemid 38697430)
21. Yao D, Gu Z, Nakamura T, et al. Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity. Proc Natl Acad Sci U S A 2004;101:10810-14 (Pubitemid 38955824)
22. LaVoie MJ, Ostaszewski BL, Weihofen A, et al. Dopamine covalently modifies and functionally inactivates parkin. Nat Med 2005;11:1214-21 (Pubitemid 43093669)
23. Ng CH, Mok SZ, Koh C, et al. Parkin protects against LRRK2 G2019S mutant-induced dopaminergic neurodegeneration in Drosophila. J Neurosci 2009;29:11257-62
24. Yang Y, Gehrke S, Imai Y, et al. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of Drosophila Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A 2006;103:10793-98 (Pubitemid 44078055)
25. Vercammen L, Van der Perren A, Vaudano E, et al. Parkin protects against neurotoxicity in the 6-hydroxydopamine rat model for Parkinson's disease. Mol Ther 2006;14:716-23 (Pubitemid 44507714)
26. Paterna JC, Leng A, Weber E, et al. DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice. Mol Ther 2007;15:698-704 (Pubitemid 46431989)
27. Yamada M, Mizuno Y, Mochizuki H. Parkin gene therapy for alphasynucleinopathy: A rat model of Parkinson's disease. Hum Gene Ther 2005;16:262-70 (Pubitemid 40344217)
28. Yasuda T, Miyachi S, Kitagawa R, et al. Neuronal specificity of alphasynuclein toxicity and effect of Parkin co-expression in primates. Neuroscience 2007;144:743-53 (Pubitemid 44855304)
29. Whitworth AJ, Pallanck LJ. The PINK1/Parkin pathway: A mitochondrial quality control system? J Bioenerg Biomembr 2009;41:499-503
30. Vives-Bauza C, Zhou C, Huang Y, et al. PINK1-dependent recruitment of Parkin to mitochondria in mitophagy. Proc Natl Acad Sci U S A 2010;107:378-83
31. Narendra DP, Jin SM, Tanaka A, et al. PINK1 is selectively stabilized on impaired mitochondria to activate Parkin. PLoS Biol 2010;8:e1000298
32. Geisler S, Holmstrom KM, Skujat D, et al. PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1. Nat Cell Biol 2010;12:119-31
33. Matsuda N, Sato S, Shiba K, et al. PINK1 stabilized by mitochondrial depolarization recruits Parkin to damaged mitochondria and activates latent Parkin for mitophagy. J Cell Biol 2010;189:211-21
34. Yamada M, Iwatsubo T, Mizuno Y, et al. Overexpression of alphasynuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: Resemblance to pathogenetic changes in Parkinson's disease. J Neurochem 2004;91:451-61 (Pubitemid 39363444)
35. Yasuda T, Nihira T, Ren YR, et al. Effects of UCH-L1 on alpha-synuclein over-expression mouse model of Parkinson's disease. J Neurochem 2009;108:932-44
36. Przedborski S, Jackson-Lewis V, Naini AB, et al. The parkinsonian toxin 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): A technical review of its utility and safety. J Neurochem 2001;76:1265-74 (Pubitemid 32198231)
37. Da Cunha C, Wietzikoski EC, Ferro MM, et al. Hemiparkinsonian rats rotate toward the side with the weaker dopaminergic neurotransmission. Behav Brain Res 2008;189:364-72
38. Furuya T, Hayakawa H, Yamada M, et al. Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. J Neurosci 2004;24:1865-72 (Pubitemid 38292797)
39. Fornai F, Schluter OM, Lenzi P, et al. Parkinson-like syndrome induced by continuous MPTP infusion: Convergent roles of the ubiquitinproteasome system and alpha-synuclein. Proc Natl Acad Sci U S A 2005;102:3413-18 (Pubitemid 40328059)
40. Fujiwara H, Hasegawa M, Dohmae N, et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 2002;4:160-64
41. Cao XQ, Arai H, Ren YR, et al. Recombinant human granulocyte colony-stimulating factor protects against MPTP-induced dopaminergic cell death in mice by altering Bcl-2/Bax expression levels. J Neurochem 2006;99:861-67 (Pubitemid 44583445)
42. Alvarez-Fischer D, Guerreiro S, Hunot S, et al. Modelling Parkinson-like neurodegeneration via osmotic minipump delivery of MPTP and probenecid. J Neurochem 2008;107:701-11
43. Burger C, Gorbatyuk OS, Velardo MJ, et al. Recombinant AAV viral vectors pseudotyped with viral capsids from serotypes 1, 2, and 5 display differential efficiency and cell tropism after delivery to different regions of the central nervous system. Mol Ther 2004;10:302-17 (Pubitemid 39117875)
44. Mandel RJ, Manfredsson FP, Foust KD, et al. Recombinant adenoassociated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther 2006;13:463-83 (Pubitemid 43257615)
45. Mochizuki H, Yasuda T, Mouradian MM. Advances in gene therapy for movement disorders. Neurotherapeutics 2008;5:260-69 (Pubitemid 351446210)
46. Manfredsson FP, Burger C, Sullivan LF, et al. rAAV-mediated nigral human parkin over-expression partially ameliorates motor deficits via enhanced dopamine neurotransmission in a rat model of Parkinson's disease. Exp Neurol 2007;207:289-301 (Pubitemid 47429661)
47. Chen L, Feany MB. alpha-Synuclein phosphorylation controls neurotoxicity and inclusion formation in a Drosophila model of Parkinson disease. Nat Neurosci 2005;8:657-63 (Pubitemid 40594208)
48. Gorbatyuk OS, Li S, Sullivan LF, et al. The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A 2008;105:763-68 (Pubitemid 351171782)
49. Azeredo da Silveira S, Schneider BL, Cifuentes-Diaz C, et al. Phosphorylation does not prompt, nor prevent, the formation of alpha-synuclein toxic species in a rat model of Parkinson's disease. Hum Mol Genet 2009;18:872-87
50. Chen L, Periquet M, Wang X, et al. Tyrosine and serine phosphorylation of alpha-synuclein have opposing effects on neurotoxicity and soluble oligomer formation. J Clin Invest 2009;119:3257-65
51. McFarland NR, Fan Z, Xu K, et al. alpha-Synuclein S129 phosphorylation mutants do not alter nigrostriatal toxicity in a rat model of Parkinson disease. J Neuropathol Exp Neurol 2009;68:515-24
52. Fallon L, Belanger CM, Corera AT, et al. A regulated interaction with the UIM protein Eps15 implicates parkin in EGF receptor trafficking and PI (3) K-Akt signalling. Nat Cell Biol 2006;8:834-42 (Pubitemid 44151586)
53. Ries V, Henchcliffe C, Kareva T, et al. Oncoprotein Akt/PKB induces trophic effects in murine models of Parkinson's disease. Proc Natl Acad Sci U S A 2006;103:18757-62 (Pubitemid 44913483)
54. Aleyasin H, Rousseaux MW, Marcogliese PC, et al. DJ-1 protects the nigrostriatal axis from the neurotoxin MPTP by modulation of the AKT pathway. Proc Natl Acad Sci U S A 2010;107:3186-91
55. da Costa CA, Sunyach C, Giaime E, et al. Transcriptional repression of p53 by parkin and impairment by mutations associated with autosomal recessive juvenile Parkinson's disease. Nat Cell Biol 2009;11:1370-75
56. Shiba K, Arai T, Sato S, et al. Parkin stabilizes PINK1 through direct interaction. Biochem Biophys Res Commun 2009;383:331-35
57. Mochizuki H. Parkin gene therapy. Parkinsonism Relat Disord 2009;15:S43-45